Industry Research Reports

Home > Reports > Medical Care > Graft Versus Host Disease Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Graft Versus Host Disease Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-11

Pages: 129 Pages

Report ld: 2638942

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

The global market for Graft Versus Host Disease Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Graft Versus Host Disease Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Graft Versus Host Disease Treatment by region & country, by Type, and by Application.

The Graft Versus Host Disease Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Graft Versus Host Disease Treatment.

Market Segmentation

Report Metric
Details
Report Title
Graft Versus Host Disease Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Graft Versus Host Disease Treatment Companies Covered
AbbVie Inc., Acrofan, Astellas Pharma Inc., Bristol-Myers Squibb Company, ElsaLys Biotech SA, F. Hoffmann-La Roche AG, Johnson & Johnson, Mallinckrodft PLC, Merck & Co., Inc., Mesoblast Limited, Neovii Biotech GmbH, Novartis AG, Ocugen, Inc., Pfizer Inc, Pluristem Therapeutics Inc., Samedan Ltd, Sanofi SA, Soligenix, Inc.
Global Graft Versus Host Disease Treatment Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Graft Versus Host Disease Treatment Market, Segment by Type
Etanercept

Monoclonal Antibodies

Thalidomide

Tyrosine Kinase Inhibitors

mTOR Inhibitors
Global Graft Versus Host Disease Treatment Market, Segment by Application
Acute GVHD

Chronic GVHD

Prophylaxis GVHD
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Graft Versus Host Disease Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Graft Versus Host Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Graft Versus Host Disease Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Graft Versus Host Disease Treatment Product Introduction
    1.2 Global Graft Versus Host Disease Treatment Market Size Forecast
    1.3 Graft Versus Host Disease Treatment Market Trends & Drivers
        1.3.1 Graft Versus Host Disease Treatment Industry Trends
        1.3.2 Graft Versus Host Disease Treatment Market Drivers & Opportunity
        1.3.3 Graft Versus Host Disease Treatment Market Challenges
        1.3.4 Graft Versus Host Disease Treatment Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Graft Versus Host Disease Treatment Players Revenue Ranking (2023)
    2.2 Global Graft Versus Host Disease Treatment Revenue by Company (2019-2024)
    2.3 Key Companies Graft Versus Host Disease Treatment Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Graft Versus Host Disease Treatment Product Offered
    2.5 Key Companies Time to Begin Mass Production of Graft Versus Host Disease Treatment
    2.6 Graft Versus Host Disease Treatment Market Competitive Analysis
        2.6.1 Graft Versus Host Disease Treatment Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Graft Versus Host Disease Treatment Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Graft Versus Host Disease Treatment as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Etanercept
        3.1.2 Monoclonal Antibodies
        3.1.3 Thalidomide
        3.1.4 Tyrosine Kinase Inhibitors
        3.1.5 mTOR Inhibitors
    3.2 Global Graft Versus Host Disease Treatment Sales Value by Type
        3.2.1 Global Graft Versus Host Disease Treatment Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Graft Versus Host Disease Treatment Sales Value, by Type (2019-2030)
        3.2.3 Global Graft Versus Host Disease Treatment Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Acute GVHD
        4.1.2 Chronic GVHD
        4.1.3 Prophylaxis GVHD
    4.2 Global Graft Versus Host Disease Treatment Sales Value by Application
        4.2.1 Global Graft Versus Host Disease Treatment Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Graft Versus Host Disease Treatment Sales Value, by Application (2019-2030)
        4.2.3 Global Graft Versus Host Disease Treatment Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Graft Versus Host Disease Treatment Sales Value by Region
        5.1.1 Global Graft Versus Host Disease Treatment Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Graft Versus Host Disease Treatment Sales Value by Region (2019-2024)
        5.1.3 Global Graft Versus Host Disease Treatment Sales Value by Region (2025-2030)
        5.1.4 Global Graft Versus Host Disease Treatment Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Graft Versus Host Disease Treatment Sales Value, 2019-2030
        5.2.2 North America Graft Versus Host Disease Treatment Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Graft Versus Host Disease Treatment Sales Value, 2019-2030
        5.3.2 Europe Graft Versus Host Disease Treatment Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Graft Versus Host Disease Treatment Sales Value, 2019-2030
        5.4.2 Asia Pacific Graft Versus Host Disease Treatment Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Graft Versus Host Disease Treatment Sales Value, 2019-2030
        5.5.2 South America Graft Versus Host Disease Treatment Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Graft Versus Host Disease Treatment Sales Value, 2019-2030
        5.6.2 Middle East & Africa Graft Versus Host Disease Treatment Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Graft Versus Host Disease Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Graft Versus Host Disease Treatment Sales Value
    6.3 United States
        6.3.1 United States Graft Versus Host Disease Treatment Sales Value, 2019-2030
        6.3.2 United States Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Graft Versus Host Disease Treatment Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Graft Versus Host Disease Treatment Sales Value, 2019-2030
        6.4.2 Europe Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Graft Versus Host Disease Treatment Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Graft Versus Host Disease Treatment Sales Value, 2019-2030
        6.5.2 China Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Graft Versus Host Disease Treatment Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Graft Versus Host Disease Treatment Sales Value, 2019-2030
        6.6.2 Japan Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Graft Versus Host Disease Treatment Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Graft Versus Host Disease Treatment Sales Value, 2019-2030
        6.7.2 South Korea Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Graft Versus Host Disease Treatment Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Graft Versus Host Disease Treatment Sales Value, 2019-2030
        6.8.2 Southeast Asia Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Graft Versus Host Disease Treatment Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Graft Versus Host Disease Treatment Sales Value, 2019-2030
        6.9.2 India Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Graft Versus Host Disease Treatment Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 AbbVie Inc.
        7.1.1 AbbVie Inc. Profile
        7.1.2 AbbVie Inc. Main Business
        7.1.3 AbbVie Inc. Graft Versus Host Disease Treatment Products, Services and Solutions
        7.1.4 AbbVie Inc. Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.1.5 AbbVie Inc. Recent Developments
    7.2 Acrofan
        7.2.1 Acrofan Profile
        7.2.2 Acrofan Main Business
        7.2.3 Acrofan Graft Versus Host Disease Treatment Products, Services and Solutions
        7.2.4 Acrofan Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.2.5 Acrofan Recent Developments
    7.3 Astellas Pharma Inc.
        7.3.1 Astellas Pharma Inc. Profile
        7.3.2 Astellas Pharma Inc. Main Business
        7.3.3 Astellas Pharma Inc. Graft Versus Host Disease Treatment Products, Services and Solutions
        7.3.4 Astellas Pharma Inc. Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.3.5 Bristol-Myers Squibb Company Recent Developments
    7.4 Bristol-Myers Squibb Company
        7.4.1 Bristol-Myers Squibb Company Profile
        7.4.2 Bristol-Myers Squibb Company Main Business
        7.4.3 Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Products, Services and Solutions
        7.4.4 Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.4.5 Bristol-Myers Squibb Company Recent Developments
    7.5 ElsaLys Biotech SA
        7.5.1 ElsaLys Biotech SA Profile
        7.5.2 ElsaLys Biotech SA Main Business
        7.5.3 ElsaLys Biotech SA Graft Versus Host Disease Treatment Products, Services and Solutions
        7.5.4 ElsaLys Biotech SA Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.5.5 ElsaLys Biotech SA Recent Developments
    7.6 F. Hoffmann-La Roche AG
        7.6.1 F. Hoffmann-La Roche AG Profile
        7.6.2 F. Hoffmann-La Roche AG Main Business
        7.6.3 F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Products, Services and Solutions
        7.6.4 F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.6.5 F. Hoffmann-La Roche AG Recent Developments
    7.7 Johnson & Johnson
        7.7.1 Johnson & Johnson Profile
        7.7.2 Johnson & Johnson Main Business
        7.7.3 Johnson & Johnson Graft Versus Host Disease Treatment Products, Services and Solutions
        7.7.4 Johnson & Johnson Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.7.5 Johnson & Johnson Recent Developments
    7.8 Mallinckrodft PLC
        7.8.1 Mallinckrodft PLC Profile
        7.8.2 Mallinckrodft PLC Main Business
        7.8.3 Mallinckrodft PLC Graft Versus Host Disease Treatment Products, Services and Solutions
        7.8.4 Mallinckrodft PLC Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.8.5 Mallinckrodft PLC Recent Developments
    7.9 Merck & Co., Inc.
        7.9.1 Merck & Co., Inc. Profile
        7.9.2 Merck & Co., Inc. Main Business
        7.9.3 Merck & Co., Inc. Graft Versus Host Disease Treatment Products, Services and Solutions
        7.9.4 Merck & Co., Inc. Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.9.5 Merck & Co., Inc. Recent Developments
    7.10 Mesoblast Limited
        7.10.1 Mesoblast Limited Profile
        7.10.2 Mesoblast Limited Main Business
        7.10.3 Mesoblast Limited Graft Versus Host Disease Treatment Products, Services and Solutions
        7.10.4 Mesoblast Limited Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.10.5 Mesoblast Limited Recent Developments
    7.11 Neovii Biotech GmbH
        7.11.1 Neovii Biotech GmbH Profile
        7.11.2 Neovii Biotech GmbH Main Business
        7.11.3 Neovii Biotech GmbH Graft Versus Host Disease Treatment Products, Services and Solutions
        7.11.4 Neovii Biotech GmbH Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.11.5 Neovii Biotech GmbH Recent Developments
    7.12 Novartis AG
        7.12.1 Novartis AG Profile
        7.12.2 Novartis AG Main Business
        7.12.3 Novartis AG Graft Versus Host Disease Treatment Products, Services and Solutions
        7.12.4 Novartis AG Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.12.5 Novartis AG Recent Developments
    7.13 Ocugen, Inc.
        7.13.1 Ocugen, Inc. Profile
        7.13.2 Ocugen, Inc. Main Business
        7.13.3 Ocugen, Inc. Graft Versus Host Disease Treatment Products, Services and Solutions
        7.13.4 Ocugen, Inc. Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.13.5 Ocugen, Inc. Recent Developments
    7.14 Pfizer Inc
        7.14.1 Pfizer Inc Profile
        7.14.2 Pfizer Inc Main Business
        7.14.3 Pfizer Inc Graft Versus Host Disease Treatment Products, Services and Solutions
        7.14.4 Pfizer Inc Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.14.5 Pfizer Inc Recent Developments
    7.15 Pluristem Therapeutics Inc.
        7.15.1 Pluristem Therapeutics Inc. Profile
        7.15.2 Pluristem Therapeutics Inc. Main Business
        7.15.3 Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Products, Services and Solutions
        7.15.4 Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.15.5 Pluristem Therapeutics Inc. Recent Developments
    7.16 Samedan Ltd
        7.16.1 Samedan Ltd Profile
        7.16.2 Samedan Ltd Main Business
        7.16.3 Samedan Ltd Graft Versus Host Disease Treatment Products, Services and Solutions
        7.16.4 Samedan Ltd Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.16.5 Samedan Ltd Recent Developments
    7.17 Sanofi SA
        7.17.1 Sanofi SA Profile
        7.17.2 Sanofi SA Main Business
        7.17.3 Sanofi SA Graft Versus Host Disease Treatment Products, Services and Solutions
        7.17.4 Sanofi SA Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.17.5 Sanofi SA Recent Developments
    7.18 Soligenix, Inc.
        7.18.1 Soligenix, Inc. Profile
        7.18.2 Soligenix, Inc. Main Business
        7.18.3 Soligenix, Inc. Graft Versus Host Disease Treatment Products, Services and Solutions
        7.18.4 Soligenix, Inc. Graft Versus Host Disease Treatment Revenue (US$ Million) & (2019-2024)
        7.18.5 Soligenix, Inc. Recent Developments

 8 Industry Chain Analysis
    8.1 Graft Versus Host Disease Treatment Industrial Chain
    8.2 Graft Versus Host Disease Treatment Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Graft Versus Host Disease Treatment Sales Model
        8.5.2 Sales Channel
        8.5.3 Graft Versus Host Disease Treatment Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Graft Versus Host Disease Treatment Market Trends
    Table 2. Graft Versus Host Disease Treatment Market Drivers & Opportunity
    Table 3. Graft Versus Host Disease Treatment Market Challenges
    Table 4. Graft Versus Host Disease Treatment Market Restraints
    Table 5. Global Graft Versus Host Disease Treatment Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Graft Versus Host Disease Treatment Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Graft Versus Host Disease Treatment Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Graft Versus Host Disease Treatment Product Type
    Table 9. Key Companies Time to Begin Mass Production of Graft Versus Host Disease Treatment
    Table 10. Global Graft Versus Host Disease Treatment Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Graft Versus Host Disease Treatment as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Graft Versus Host Disease Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Graft Versus Host Disease Treatment Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Graft Versus Host Disease Treatment Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Graft Versus Host Disease Treatment Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Graft Versus Host Disease Treatment Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Graft Versus Host Disease Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Graft Versus Host Disease Treatment Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Graft Versus Host Disease Treatment Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Graft Versus Host Disease Treatment Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Graft Versus Host Disease Treatment Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Graft Versus Host Disease Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Graft Versus Host Disease Treatment Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Graft Versus Host Disease Treatment Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Graft Versus Host Disease Treatment Sales Value by Region (2019-2024) & (%)
    Table 27. Global Graft Versus Host Disease Treatment Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Graft Versus Host Disease Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Graft Versus Host Disease Treatment Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Graft Versus Host Disease Treatment Sales Value, (2025-2030) & (US$ Million)
    Table 31. AbbVie Inc. Basic Information List
    Table 32. AbbVie Inc. Description and Business Overview
    Table 33. AbbVie Inc. Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of AbbVie Inc. (2019-2024)
    Table 35. AbbVie Inc. Recent Developments
    Table 36. Acrofan Basic Information List
    Table 37. Acrofan Description and Business Overview
    Table 38. Acrofan Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Acrofan (2019-2024)
    Table 40. Acrofan Recent Developments
    Table 41. Astellas Pharma Inc. Basic Information List
    Table 42. Astellas Pharma Inc. Description and Business Overview
    Table 43. Astellas Pharma Inc. Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Astellas Pharma Inc. (2019-2024)
    Table 45. Astellas Pharma Inc. Recent Developments
    Table 46. Bristol-Myers Squibb Company Basic Information List
    Table 47. Bristol-Myers Squibb Company Description and Business Overview
    Table 48. Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Bristol-Myers Squibb Company (2019-2024)
    Table 50. Bristol-Myers Squibb Company Recent Developments
    Table 51. ElsaLys Biotech SA Basic Information List
    Table 52. ElsaLys Biotech SA Description and Business Overview
    Table 53. ElsaLys Biotech SA Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of ElsaLys Biotech SA (2019-2024)
    Table 55. ElsaLys Biotech SA Recent Developments
    Table 56. F. Hoffmann-La Roche AG Basic Information List
    Table 57. F. Hoffmann-La Roche AG Description and Business Overview
    Table 58. F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of F. Hoffmann-La Roche AG (2019-2024)
    Table 60. F. Hoffmann-La Roche AG Recent Developments
    Table 61. Johnson & Johnson Basic Information List
    Table 62. Johnson & Johnson Description and Business Overview
    Table 63. Johnson & Johnson Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Johnson & Johnson (2019-2024)
    Table 65. Johnson & Johnson Recent Developments
    Table 66. Mallinckrodft PLC Basic Information List
    Table 67. Mallinckrodft PLC Description and Business Overview
    Table 68. Mallinckrodft PLC Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Mallinckrodft PLC (2019-2024)
    Table 70. Mallinckrodft PLC Recent Developments
    Table 71. Merck & Co., Inc. Basic Information List
    Table 72. Merck & Co., Inc. Description and Business Overview
    Table 73. Merck & Co., Inc. Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Merck & Co., Inc. (2019-2024)
    Table 75. Merck & Co., Inc. Recent Developments
    Table 76. Mesoblast Limited Basic Information List
    Table 77. Mesoblast Limited Description and Business Overview
    Table 78. Mesoblast Limited Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Mesoblast Limited (2019-2024)
    Table 80. Mesoblast Limited Recent Developments
    Table 81. Neovii Biotech GmbH Basic Information List
    Table 82. Neovii Biotech GmbH Description and Business Overview
    Table 83. Neovii Biotech GmbH Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Neovii Biotech GmbH (2019-2024)
    Table 85. Neovii Biotech GmbH Recent Developments
    Table 86. Novartis AG Basic Information List
    Table 87. Novartis AG Description and Business Overview
    Table 88. Novartis AG Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Novartis AG (2019-2024)
    Table 90. Novartis AG Recent Developments
    Table 91. Ocugen, Inc. Basic Information List
    Table 92. Ocugen, Inc. Description and Business Overview
    Table 93. Ocugen, Inc. Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Ocugen, Inc. (2019-2024)
    Table 95. Ocugen, Inc. Recent Developments
    Table 96. Pfizer Inc Basic Information List
    Table 97. Pfizer Inc Description and Business Overview
    Table 98. Pfizer Inc Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Pfizer Inc (2019-2024)
    Table 100. Pfizer Inc Recent Developments
    Table 101. Pluristem Therapeutics Inc. Basic Information List
    Table 102. Pluristem Therapeutics Inc. Description and Business Overview
    Table 103. Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Pluristem Therapeutics Inc. (2019-2024)
    Table 105. Pluristem Therapeutics Inc. Recent Developments
    Table 106. Samedan Ltd Basic Information List
    Table 107. Samedan Ltd Description and Business Overview
    Table 108. Samedan Ltd Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 109. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Samedan Ltd (2019-2024)
    Table 110. Samedan Ltd Recent Developments
    Table 111. Sanofi SA Basic Information List
    Table 112. Sanofi SA Description and Business Overview
    Table 113. Sanofi SA Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 114. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Sanofi SA (2019-2024)
    Table 115. Sanofi SA Recent Developments
    Table 116. Soligenix, Inc. Basic Information List
    Table 117. Soligenix, Inc. Description and Business Overview
    Table 118. Soligenix, Inc. Graft Versus Host Disease Treatment Products, Services and Solutions
    Table 119. Revenue (US$ Million) in Graft Versus Host Disease Treatment Business of Soligenix, Inc. (2019-2024)
    Table 120. Soligenix, Inc. Recent Developments
    Table 121. Key Raw Materials Lists
    Table 122. Raw Materials Key Suppliers Lists
    Table 123. Graft Versus Host Disease Treatment Downstream Customers
    Table 124. Graft Versus Host Disease Treatment Distributors List
    Table 125. Research Programs/Design for This Report
    Table 126. Key Data Information from Secondary Sources
    Table 127. Key Data Information from Primary Sources
    Table 128. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Graft Versus Host Disease Treatment Product Picture
    Figure 2. Global Graft Versus Host Disease Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Graft Versus Host Disease Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 4. Graft Versus Host Disease Treatment Report Years Considered
    Figure 5. Global Graft Versus Host Disease Treatment Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Graft Versus Host Disease Treatment Revenue in 2023
    Figure 7. Graft Versus Host Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Etanercept Picture
    Figure 9. Monoclonal Antibodies Picture
    Figure 10. Thalidomide Picture
    Figure 11. Tyrosine Kinase Inhibitors Picture
    Figure 12. mTOR Inhibitors Picture
    Figure 13. Global Graft Versus Host Disease Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Graft Versus Host Disease Treatment Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Product Picture of Acute GVHD
    Figure 16. Product Picture of Chronic GVHD
    Figure 17. Product Picture of Prophylaxis GVHD
    Figure 18. Global Graft Versus Host Disease Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 19. Global Graft Versus Host Disease Treatment Sales Value Market Share by Application, 2023 & 2030
    Figure 20. North America Graft Versus Host Disease Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 21. North America Graft Versus Host Disease Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 22. Europe Graft Versus Host Disease Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 23. Europe Graft Versus Host Disease Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 24. Asia Pacific Graft Versus Host Disease Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 25. Asia Pacific Graft Versus Host Disease Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 26. South America Graft Versus Host Disease Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 27. South America Graft Versus Host Disease Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 28. Middle East & Africa Graft Versus Host Disease Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 29. Middle East & Africa Graft Versus Host Disease Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 30. Key Countries/Regions Graft Versus Host Disease Treatment Sales Value (%), (2019-2030)
    Figure 31. United States Graft Versus Host Disease Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 32. United States Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 33. United States Graft Versus Host Disease Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 34. Europe Graft Versus Host Disease Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 35. Europe Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 36. Europe Graft Versus Host Disease Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 37. China Graft Versus Host Disease Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 38. China Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 39. China Graft Versus Host Disease Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 40. Japan Graft Versus Host Disease Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 41. Japan Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 42. Japan Graft Versus Host Disease Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 43. South Korea Graft Versus Host Disease Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 44. South Korea Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 45. South Korea Graft Versus Host Disease Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 46. Southeast Asia Graft Versus Host Disease Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 47. Southeast Asia Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 48. Southeast Asia Graft Versus Host Disease Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 49. India Graft Versus Host Disease Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 50. India Graft Versus Host Disease Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 51. India Graft Versus Host Disease Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 52. Graft Versus Host Disease Treatment Industrial Chain
    Figure 53. Graft Versus Host Disease Treatment Manufacturing Cost Structure
    Figure 54. Channels of Distribution (Direct Sales, and Distribution)
    Figure 55. Bottom-up and Top-down Approaches for This Report
    Figure 56. Data Triangulation

Description

The global market for Graft Versus Host Disease Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Graft Versus Host Disease Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Graft Versus Host Disease Treatment by region & country, by Type, and by Application.

The Graft Versus Host Disease Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Graft Versus Host Disease Treatment.

Market Segmentation